003120.KS
Ilsung Pharmaceuticals Co., Ltd. [003120.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
003120.KS Stock Summary
Top 10 Correlated ETFs
003120.KS
Top 10 Correlated Stocks
003120.KS
In the News
003120.KS Financial details
Company Rating
Sell
Market Cap
140.4B
Income
-20.94B
Revenue
78.05B
Book val./share
56157.87
Cash/share
34541
Dividend
-
Dividend %
-
Employees
224
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
5.55
Forward P/E
-
PEG
-0.26
P/S
3.65
P/B
0.27
P/C
0.54
P/FCF
-0.65
Quick Ratio
-
Current Ratio
14.1
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-3.22K
EPS next Y
-
EPS next Q
-
EPS this Y
-203.02%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
10.02%
Revenue Q/Q
21.84%
EPS Q/Q
-985.96%
-
-
-
-
SMA20
-11.39%
SMA50
-13.45%
SMA100
-4.49%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
5%
ROC
-0.01%
Gross Margin
48%
Oper. Margin
-5%
Profit Margin
28%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
18710.0-31950.0
52W High
-42.1%
52W Low
-1.12%
RSI
20.12
Rel Volume
1.79
Avg Volume
18.34K
Volume
32.75K
Perf Week
-10.84%
Perf Month
-16.67%
Perf Quarter
-10.19%
Perf Half Y
-15.91%
-
-
-
-
Beta
-0.17
-
-
Volatility
781.71%, 1194.36%
Prev Close
-3.04%
Price
18500
Change
-2.63%
003120.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 7K | 5.29K | 5.49K | 1.64K | 11.16K | |
| Net income per share | 971.72 | 419.91 | -178.32 | 2.91K | -2.99K | |
| Operating cash flow per share | 634.75 | 203.07 | 743.8 | -1.04K | -5.68K | |
| Free cash flow per share | 455.35 | -425.11 | -901.57 | -2.71K | -6.78K | |
| Cash per share | 7.52K | 5.9K | 8.36K | 8.02K | 33.66K | |
| Book value per share | 49.97K | 45.31K | 45.11K | 11.92K | 54.73K | |
| Tangible book value per share | 49.93K | 45.27K | 44.86K | 11.86K | 54.39K | |
| Share holders equity per share | 49.97K | 45.31K | 45.11K | 11.92K | 54.73K | |
| Interest debt per share | 17.72 | 59.38 | 25.26 | 7.68 | 37.46 | |
| Market cap | 113.53B | 126.84B | 113.19B | 631.12B | 158.4B | |
| Enterprise value | 76.38B | 91.06B | 62.53B | 358.47B | -1.45B | |
| P/E ratio | 16.9 | 39.39 | -82.77 | 5.81 | -7.56 | |
| Price to sales ratio | 2.35 | 3.12 | 2.69 | 10.3 | 2.03 | |
| POCF ratio | 25.87 | 81.45 | 19.84 | -16.2 | -3.99 | |
| PFCF ratio | 36.06 | -38.91 | -16.37 | -6.22 | -3.34 | |
| P/B Ratio | 0.33 | 0.37 | 0.33 | 1.42 | 0.41 | |
| PTB ratio | 0.33 | 0.37 | 0.33 | 1.42 | 0.41 | |
| EV to sales | 1.58 | 2.24 | 1.49 | 5.85 | -0.02 | |
| Enterprise value over EBITDA | 23.06 | 32.99 | 13.3 | 2.5 | 0.29 | |
| EV to operating cash flow | 17.4 | 58.48 | 10.96 | -9.2 | 0.04 | |
| EV to free cash flow | 24.26 | -27.93 | -9.04 | -3.53 | 0.03 | |
| Earnings yield | 0.06 | 0.03 | -0.01 | 0.17 | -0.13 | |
| Free cash flow yield | 0.03 | -0.03 | -0.06 | -0.16 | -0.3 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -11.22 | -12.96 | -10.77 | -1.9 | 32.58 | |
| Current ratio | 14.87 | 15.65 | 13.51 | 8.08 | 8.42 | |
| Interest coverage | 41.65 | -21.5 | 128.91 | 11.1K | -324.87 | |
| Income quality | 0.65 | 0.48 | -4.17 | -0.37 | 1.9 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0 | 0.19 | |
| Payout ratio | 0.15 | 0.36 | -0.84 | 0.01 | -1.42 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | |
| Research and developement to revenue | 0 | 0 | 0 | 0.02 | 0.02 | |
| Intangibles to total assets | 0 | 0 | 0.01 | 0 | 0.01 | |
| Capex to operating cash flow | -0.28 | -3.09 | -2.21 | 1.6 | 0.19 | |
| Capex to revenue | -0.03 | -0.12 | -0.3 | -1.02 | -0.1 | |
| Capex to depreciation | -0.4 | -1.57 | -4.1 | -20.2 | -2.71 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 33.05K | 20.69K | 13.45K | 27.92K | 60.72K | |
| ROIC | 0 | 0 | 0 | 0.24 | -0.02 | |
| Return on tangible assets | 0.02 | 0.01 | 0 | 0.22 | -0.05 | |
| Graham Net | 27.43K | 23.69K | 25.74K | 7.46K | 33.34K | |
| Working capital | 254.12B | 246.42B | 259.24B | 301.35B | 259.05B | |
| Tangible asset value | 345.19B | 347.2B | 343.99B | 443.28B | 380.38B | |
| Net current asset value | 248.41B | 239.5B | 254.49B | 295.05B | 257.51B | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 207.99B | 205.52B | 204.1B | 113.35B | 24.06B | |
| Average payables | 2.33B | 2.21B | 1.43B | 2.9B | 5.41B | |
| Average inventory | 14.77B | 13.64B | 12.81B | 16.56B | 25.94B | |
| Days sales outstanding | 1.55K | 1.84K | 1.76K | 139.05 | 115.93 | |
| Days payables outstanding | 28.1 | 27.96 | 10.66 | 55.34 | 48.54 | |
| Days of inventory on hand | 170.72 | 174.82 | 175.48 | 226.16 | 263.12 | |
| Receivables turnover | 0.23 | 0.2 | 0.21 | 2.62 | 3.15 | |
| Payables turnover | 12.99 | 13.06 | 34.23 | 6.6 | 7.52 | |
| Inventory turnover | 2.14 | 2.09 | 2.08 | 1.61 | 1.39 | |
| ROE | 0.02 | 0.01 | 0 | 0.24 | -0.05 | |
| Capex per share | -179.4 | -628.18 | -1.65K | -1.67K | -1.1K |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.31K | 2.45K | 2.85K | 2.65K | 3.23K | |
| Net income per share | 205.31 | 2.12K | -172.87 | 657.53 | -5.83K | |
| Operating cash flow per share | -45.08K | -1.09K | -2.01K | -1.13K | -5.43K | |
| Free cash flow per share | -52.88K | -1.2K | -2.21K | -1.51K | -5.85K | |
| Cash per share | 40.45K | 42.03K | 35.4K | 36.24K | 34.54K | |
| Book value per share | 60.1K | 58.32K | 59.11K | 61.59K | 56.16K | |
| Tangible book value per share | 59.79K | 58.01K | 58.77K | 61.23K | 55.81K | |
| Share holders equity per share | 60.1K | 58.32K | 59.11K | 61.59K | 56.16K | |
| Interest debt per share | 37.5 | -3.22K | 29.28 | 41.96 | 36.61 | |
| Market cap | 125.15B | 204.92B | 184.8B | 144.49B | 154.37B | |
| Enterprise value | -147.49B | -75.45B | -38.39B | -76.74B | -5.47B | |
| P/E ratio | 20.55 | 3.31 | -38.04 | 8.06 | -0.97 | |
| Price to sales ratio | 7.3 | 11.43 | 9.23 | 7.99 | 7.01 | |
| POCF ratio | -0.37 | -25.58 | -13.09 | -18.76 | -4.17 | |
| PFCF ratio | -0.32 | -23.38 | -11.87 | -14.02 | -3.87 | |
| P/B Ratio | 0.28 | 0.48 | 0.44 | 0.34 | 0.4 | |
| PTB ratio | 0.28 | 0.48 | 0.44 | 0.34 | 0.4 | |
| EV to sales | -8.6 | -4.21 | -1.92 | -4.25 | -0.25 | |
| Enterprise value over EBITDA | -31.46 | -8.6 | -3.56 | -10.21 | 11.8 | |
| EV to operating cash flow | 0.44 | 9.42 | 2.72 | 9.97 | 0.15 | |
| EV to free cash flow | 0.38 | 8.61 | 2.47 | 7.45 | 0.14 | |
| Earnings yield | 0.01 | 0.08 | -0.01 | 0.03 | -0.26 | |
| Free cash flow yield | -3.13 | -0.04 | -0.08 | -0.07 | -0.26 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -58.16 | -31.95 | -20.69 | -29.43 | 344.54 | |
| Current ratio | 8.08 | 5.5 | 13.24 | 14.1 | 8.42 | |
| Interest coverage | 1.04K | 0.13 | -397.48 | -503.2 | -71.64 | |
| Income quality | -219.57 | -0.52 | 11.62 | -1.72 | 0.93 | |
| Dividend Yield | 0 | 0 | 0.16 | 0 | 0 | |
| Payout ratio | 0 | 0 | -24.42 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.66 | 0.67 | 0.5 | 0.03 | |
| Research and developement to revenue | 0.01 | 0.02 | 0 | 0.02 | 0.01 | |
| Intangibles to total assets | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.17 | 0.09 | 0.1 | 0.34 | 0.08 | |
| Capex to revenue | -3.37 | -0.04 | -0.07 | -0.14 | -0.13 | |
| Capex to depreciation | -67.24 | -0.84 | -1.56 | -2.88 | -8.3 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 16.66K | 52.69K | 15.16K | 30.18K | 85.79K | |
| ROIC | 0.01 | -0.01 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | 0.03 | 0 | 0.01 | -0.1 | |
| Graham Net | 37.62K | 35.79K | 34.73K | 36.14K | 34.21K | |
| Working capital | 301.35B | 286.45B | 276.86B | 282.3B | 259.05B | |
| Tangible asset value | 443.28B | 424.85B | 412.97B | 417.35B | 380.38B | |
| Net current asset value | 295.05B | 278.35B | 263.94B | 269.29B | 257.51B | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 19.65B | 21.37B | 20.59B | 21.81B | 23.32B | |
| Average payables | 5.21B | 4.84B | 5.9B | 7.47B | 6.77B | |
| Average inventory | 19.47B | 21.73B | 25.9B | 32.01B | 33.14B | |
| Days sales outstanding | 122.47 | 97.46 | 97.82 | 108.77 | 101.32 | |
| Days payables outstanding | 51.93 | 45.53 | 69.84 | 66.28 | 39.75 | |
| Days of inventory on hand | 212.22 | 224.29 | 282.17 | 298.72 | 215.48 | |
| Receivables turnover | 0.73 | 0.92 | 0.92 | 0.83 | 0.89 | |
| Payables turnover | 1.73 | 1.98 | 1.29 | 1.36 | 2.26 | |
| Inventory turnover | 0.42 | 0.4 | 0.32 | 0.3 | 0.42 | |
| ROE | 0 | 0.04 | 0 | 0.01 | -0.1 | |
| Capex per share | -7.8K | -102.71 | -206.16 | -381.76 | -429 |
003120.KS Frequently Asked Questions
What is Ilsung Pharmaceuticals Co., Ltd. stock symbol ?
Ilsung Pharmaceuticals Co., Ltd. is a KR stock and trading under the symbol 003120.KS
What is Ilsung Pharmaceuticals Co., Ltd. stock quote today ?
Ilsung Pharmaceuticals Co., Ltd. stock price is $18500 today.
Is Ilsung Pharmaceuticals Co., Ltd. stock public?
Yes, Ilsung Pharmaceuticals Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 18.34K
- Market Capitalization 140.4B
- Employee 224
- CEO Mr. Seok-geun Yoon
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://www.ilsung-ph.co.kr 
Ilsung Pharmaceuticals Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, anti-coagulants, circulatory system drugs, contrast agents, diabetes treatments, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, anesthetics, antipyretics, and cardiovascular system products. Ilsung Pharmaceuticals Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.
